TY - JOUR
T1 - The preparation of soft gelatin capsules for a radioactive tracer study
AU - Tesconi, Marc S.
AU - Bramer, Steven L.
AU - Yalkowsky, Samuel H.
N1 - Funding Information:
This study was supported by Otsuka America Pharmaceuticals, Inc.
PY - 1999
Y1 - 1999
N2 - Clinical doses are developed for the oral coadministration of radiolabeled and nonlabeled forms of a poorly soluble investigational compound: OPC-41061. The release rates of the labeled and nonlabeled forms are equated and matched to the release rate of the polymer spray-dried form of the drug in the proposed market product. The study involves the physicochemical characterization of the powders using thermal analysis and dissolution testing, development and extemporaneous manufacture of liquid- filled soft gelatin capsules, and dissolution and stability testing of the final dosage form. Thermal analysis indicated that the labeled powder was amorphous and that the nonlabeled powder, which had been jet-milled, was crystalline. Dissolution testing of the jet-milled and spray-dried powders indicated that the former was released at a significantly slower rate. A liquid formulation containing 25% dimethyl acetamide and 75% polyethylene glycol 400 (PEG 400) solubilized the desired dose of 60 mg and exhibited a drug profile that was similar to the spray-dried formulation. The final formulation was a soft gelatin capsule containing 60 mg of drug, including 100 μCi radioactivity, dissolved in 0.8 ml of a 25% dimethyl acetamide/75% PEG 400 solution. The formulation was chemically and physically stable for a period greater than the duration of the study.
AB - Clinical doses are developed for the oral coadministration of radiolabeled and nonlabeled forms of a poorly soluble investigational compound: OPC-41061. The release rates of the labeled and nonlabeled forms are equated and matched to the release rate of the polymer spray-dried form of the drug in the proposed market product. The study involves the physicochemical characterization of the powders using thermal analysis and dissolution testing, development and extemporaneous manufacture of liquid- filled soft gelatin capsules, and dissolution and stability testing of the final dosage form. Thermal analysis indicated that the labeled powder was amorphous and that the nonlabeled powder, which had been jet-milled, was crystalline. Dissolution testing of the jet-milled and spray-dried powders indicated that the former was released at a significantly slower rate. A liquid formulation containing 25% dimethyl acetamide and 75% polyethylene glycol 400 (PEG 400) solubilized the desired dose of 60 mg and exhibited a drug profile that was similar to the spray-dried formulation. The final formulation was a soft gelatin capsule containing 60 mg of drug, including 100 μCi radioactivity, dissolved in 0.8 ml of a 25% dimethyl acetamide/75% PEG 400 solution. The formulation was chemically and physically stable for a period greater than the duration of the study.
KW - Dissolution testing
KW - Physicochemical characterization
KW - Radioactive tracer
KW - Soft gelatin capsule
UR - http://www.scopus.com/inward/record.url?scp=0032742468&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032742468&partnerID=8YFLogxK
U2 - 10.1081/PDT-100101388
DO - 10.1081/PDT-100101388
M3 - Article
C2 - 10578504
AN - SCOPUS:0032742468
SN - 1083-7450
VL - 4
SP - 507
EP - 513
JO - Pharmaceutical Development and Technology
JF - Pharmaceutical Development and Technology
IS - 4
ER -